Pancreas cancer meets the thunder god.
A new formulation of a natural product shows remarkable activity against pancreatic ductal adenocarcinoma across a number of preclinical model systems. These findings set the stage for a clinical trial.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. srh@fhcrc.org
Sunil R
SR
Hingorani
John D
JD
Potter
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D021441:Carcinoma, Pancreatic Ductal / Q000628:therapy*; D002986:Clinical Trials as Topic; D004224:Diterpenes / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004852:Epoxy Compounds / Q000627:therapeutic use; D006801:Humans; D008495:Medical Oncology / Q000639:trends; D008516:Medicine, Chinese Traditional; D010755:Organophosphates / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000628:therapy*; D010616:Phenanthrenes / Q000627:therapeutic use; D012107:Research Design; D057170:Translational Research, Biomedical
D018906:Antineoplastic Agents, Alkylating; D004224:Diterpenes; D004852:Epoxy Compounds; D010755:Organophosphates; D010616:Phenanthrenes; C001899:triptolide; C579022:14-O-phosphonooxymethyltriptolide disodium salt